Clin2
NCT06497010Possibly a fitRecruiting

Personalized mRNA cancer vaccine for advanced solid tumors

Advanced Solid Tumor

Part of Cancer clinical trials.

This trial tests a personalized mRNA vaccine (InnoPCV) designed from your own tumor's genetic profile to train your immune system to fight advanced solid tumors. It is for people who have not had tumor vaccines or CAR-T therapy before and can provide a tumor sample for customized vaccine creation.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
40 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have an advanced solid tumor that cannot be removed surgically.
  • You are in good general health (able to be up and about, with some restrictions).
  • You have a stored tumor sample (like from an earlier surgery) that can be tested to make a personalized vaccine.
  • You have not had certain immune-based treatments before (such as CAR-T or tumor vaccines).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05916248Recruiting· Early Phase 1
mRNA vaccine plus pembrolizumab for advanced solid tumors

This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.

Shanghai, Shanghai Municipality
NCT06878612Recruiting· Phase 1
Personalized tumor cell vaccine for advanced solid tumors

This trial tests a new vaccine made from your own tumor cells to see if it can help your immune system fight the cancer. It is for people with advanced solid tumors that have not responded to other treatments.

Chengdu, Sichuan
NCT07182435Not yet recruiting· Early Phase 1
Personalized mRNA vaccine for advanced solid tumors

This trial tests a personalized mRNA cancer vaccine (RH125) for people with advanced solid tumors that have spread or cannot be removed by surgery. It may be an option if standard treatments have stopped working or are not suitable, and for some, it will be given with a PD-1 blocker.

Shenzhen, Guangdong
NCT06195384Recruiting· Phase 1
Personalized mRNA vaccine for advanced solid tumors

This trial tests a personalized mRNA vaccine made from your tumor's unique markers (neoantigens) to train your immune system to fight cancer. It is for people with advanced solid tumors who have not had gene therapy and are healthy enough for the vaccine.

Guangzhou, Guangdong
NCT06195293Recruiting· Phase 1
Personalized cancer vaccine for advanced solid tumors

This trial tests a personalized vaccine made from unique markers on your tumor cells (called neoantigens). The goal is to help your immune system fight the cancer more effectively. It is for people with advanced solid tumors who have not had gene therapy and are otherwise relatively healthy.

Guangzhou
NCT06477614Recruiting· Phase 1
Personalized vaccine for advanced solid tumors

This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help your body fight advanced cancer. It is for people whose cancer has not responded to other treatments.

Guanzhou, Guangdong

Hear when a new Advanced Solid Tumor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.